A2 Biotherapeutics, Inc.

Julyun Oh

Carl Alexander Kamb

Han Xu

Yuta Ando

The disclosure relates to immune cells comprising a dual receptor system responsive to loss of heterozygosity in a target cell, and methods of making and using same. The first receptor comprises activator receptor specific to a HER2 antigen, and the second receptor comprises an inhibitory receptor specific to an antigen lost in cancer but not wild type cells, that inhibits activation of the immune cells by the first receptor.

Compositions and methods for treating HER2 positive cancers

The disclosure provides immune cells comprising a first activator receptor and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.

Growing community of inventors

Agoura Hills, CA, United States of America

Julyun Oh